Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates
Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business
Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?
Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Senior Vice President and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - J.P. Morgan Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Bioventus Third Quarter 2024 Earnings Conference Call.
Bioventus (BVS) Matches Q3 Earnings Estimates
Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?
Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.
Bioventus Surges 73% in Three Months: Time to Buy the Stock?
BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.
Bull Of The Day: Bioventus (BVS)
This stock has seen 3 consecutive beats of the Zacks Consensus Estimate and also posted solid margin expansion.
